Related Experiment Video

Updated: Mar 29, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma

Zhong-Qian Hu1, Rui Ma2, Chi-Min Zhang1

  • 1Department of Ultrasound, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, P.R. China.

Oncology Letters
|December 2, 2015
PubMed

Insights

This study investigated the role of Protein-tyrosine phosphatase SHP2 in thyroid cancer. Increased SHP2 expression was found in thyroid tumors and correlated with advanced disease, suggesting it as a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Protein-tyrosine phosphatase SHP2, encoded by PTPN11, is implicated in various cancers.
  • SHP2 mutations are found in leukemia and solid tumors like liver, breast, gastric, and cervical cancers.
  • The significance of SHP2 expression in thyroid cancer remains largely unexplored.

Purpose of the Study:

  • To evaluate SHP2 expression levels in thyroid cancer tissues.
  • To determine the correlation between SHP2 expression and clinicopathological features of thyroid cancer.
  • To investigate the potential of SHP2 as a therapeutic target in thyroid cancer.

Main Methods:

  • Immunohistochemical and Western blot analyses were used to assess SHP2 expression in 65 thyroid cancer specimens, adjacent peritumour tissues, and normal thyroid tissues.
  • SHP2 expression was also analyzed in various thyroid cancer cell lines and normal thyroid cells.
  • SHP2 function was investigated in SW579 cells using antisense oligonucleotides and growth inhibition assays.

Main Results:

  • Significantly increased SHP2 expression was observed in thyroid tumour tissues compared to normal thyroid tissues (P<0.05).
  • Elevated SHP2 expression correlated with poor tumour differentiation (P<0.05), advanced TNM stage (P<0.05), and lymph node metastasis (P<0.05).
  • Blocking SHP2 expression in SW579 cells led to growth inhibition.

Conclusions:

  • SHP2 is overexpressed in thyroid cancer.
  • SHP2 expression is associated with aggressive clinicopathological features in thyroid cancer.
  • SHP2 represents a promising therapeutic target for thyroid cancer treatment.
Keywords:
SHP2expressionthyroid cancertumour proliferation

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

874
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.7K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K